Skip to main content
Premium Trial:

Request an Annual Quote

Genomatix, USU Seek to Use NGS to Find Prostate Cancer Prognostic Markers


Genomatix Software, the Uniformed Service University of the Health Sciences, and the Henry M. Jackson Foundation for the Advancement of Military Medicine will collaborate on a project to use next-gen sequencing to help identify biomarkers for prostate cancer prognostics.

The goal of the collaboration is to identify biomarkers that can be used to help predict the outcome of prostate cancer patients at the time of diagnosis, which is currently difficult to do.

The project will combine USUHS' Center for Prostate Diseases Research's translational research resources and expertise with Genomatix's data-analysis software to identify novel androgen receptor-binding sites to analyze prostate cancer metastasis using model systems and clinical specimens.

"Next-generation sequencing opens a new dimension in biomarker research and will allow a finer grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which also may be targets for therapeutic intervention and treatment monitoring," Genomatix founder Thomas Werner said in statement.